Table 1. Comparison of baseline characteristics between the two groups.
| Variable | Group 1 (n=29) | Group 2 (n=28) | p-valuea | |
|---|---|---|---|---|
| Age, y | 65.07±8.46 | 63.19±6.19 | 0.361 | |
| Weight, kg | 74.93±8.92 | 69.53±10.49 | 0.056 | |
| BMI, kg/m2 | 25.48±2.22 | 25.01±3.27 | 0.557 | |
| Prostate volume, g | 27.36±4.03 | 28.12±4.54 | 0.551 | |
| PSA, ng/mL | 1.12±0.76 | 0.97±0.75 | 0.351 | |
| Hemoglobin, g/dL | 15.16±1.66 | 15.54±1.01 | 0.101 | |
| Hematocrit, % | 43.61±4.38 | 45.38±3.18 | 0.273 | |
| Total cholesterol, mg/dL | 181.38±35.83 | 182.07±42.20 | 0.710 | |
| Glucose, mg/dL | 119.15±25.78 | 121.45±41.28 | 0.622 | |
| Vitamin D, ng/mL | 15.54±3.17 | 16.24±3.28 | 0.432 | |
| Testosterone, ng/mL | 460.33±138.34 | 536.20±162.48 | 0.073 | |
| Qmax, mL/s | 16.99±8.05 | 18.35±6.05 | 0.130 | |
| Postvoid urine volume, mL | 39.36±36.53 | 29.22±41.53 | 0.163 | |
| IPSS | ||||
| Total score | 8.50±3.46 | 9.89±6.01 | 0.435 | |
| QoL score | 2.25±1.16 | 2.00±1.23 | 0.603 | |
| AMS | ||||
| Somato-vegetative subscale | 11.61±4.23 | 13.67±2.70 | 0.654 | |
| Psychological subscale | 6.78±1.87 | 7.33±1.58 | 0.405 | |
| Sexual subscale | 11.28±3.51 | 10.78±3.15 | 0.052 | |
| Total score | 29.67±7.90 | 31.78±5.78 | 0.895 | |
| Comorbidities | 0.680 | |||
| Hypertension | 4/27 | 5/26 | ||
| Diabetes Mellitus | 4/27 | 3/26 | ||
| Dyslipidemia | 5/27 | 3/26 | ||
| Cerebrovascular disease | 2/27 | 1/26 | ||
| BPH-LUTS | 6/27 | 3/26 | ||
Values are presented as mean±standard deviation or number only.
BMI: body mass index, PSA: prostate-specific antigen, Qmax: uroflowmetry maximal flow rate, IPSS: International Prostate Symptom Score, QoL: quality of life, AMS: Aging Males’ Symptoms Scale, BPH-LUTS: benign prostate hyperplasia and lower urinary tract symptoms.
Group 1: vitamin D supplement group, Group 2: controls.
aIndependent t-test or chi-square test.